Our Products

Affibody aims to improve the lives of patients with serious diseases. We focus on indications and target proteins where our technology platform offers us a competitive advantage and where there is a high unmet medical need in well-defined patient populations. We run pre-clinical and clinical development programs in oncology and immunology where we selectively advance projects based on therapeutic and commercial potential.

In oncology, Affibody is developing a pipeline of novel targeted radiopharmaceuticals. Affibody^® molecules can be attached to radioactive agents. This makes it possible to tailor targeting molecules that, within minutes of being injected into the body, find and bind to a selected surface protein on tumor cells, where they remain for an extended period of time, allowing the radioactive agent to emit its radiation with high precision.

We have demonstrated that Affibody^® molecules can effectively target HER2-expressing tumors in patients with metastatic disease. Supported by experience with our advanced imaging diagnostic, tezatabep matraxetan (ABY-025), we are developing a radiation based HER2-targeted precision drug, ABY-271, for patients who no longer respond to existing treatments. Early clinical results from a first-in-human trial with ABY-271 in patients with HER2-positive metastatic breast cancer are expected during 2025.

In addition, Affibody is developing the radiotherapeutic candidate ABY-071, which targets the tumor protein B7-H3 that is overexpressed by many different types of cancers.

To complement Affibody’s proprietary radiopharmaceutical development, Affibody’s partner GE Healthcare is also developing a PET imaging candidate, GE-226, with a view to improve the diagnosis of HER2-positive cancers.

Affibody’s partner Antaros is developing a new PET tracer, ATH001, to probe the presence of platelet-related growth factor receptor beta (PDGFRβ), which is a marker of ongoing fibrogenesis in tissue.

In immunology, several clinical studies have been conducted with izokibep in IL-17 mediated diseases. The next generation IL-17 inhibitor has demonstrated best-in-class efficacy in late-stage studies in both hidradenitis suppurativa and psoriatic arthritis with a favorable safety profile. The clinical results with izokibep have validated the potential of the Affibody^® platform to generate miniaturized multispecific protein drugs that address unmet medical needs.

Affibody’s partner Rallybio is developing the drug candidate RLYB116 for complement mediated diseases. RLYB116 acts by inhibiting the activation of complement factor 5 (C5) in the complement cascade. 

In respiratory diseases, we have the drug candidate ABY-062 targeting TSLP, a cytokine with a central role in the inflammatory processes in asthma and chronic obstructive pulmonary disease (COPD). ABY-062 has the potential to develop into a long-acting inhaled treatment with efficacy superior to other compounds in its class. In addition, Affibody is collaborating with Chiesi to discover and develop novel Affibody^® molecules as innovative treatments for respiratory diseases.